采纳股份(301122) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥110,633,038.63, representing a 65.52% increase compared to ¥66,839,280.56 in the same period last year[5] - Net profit attributable to shareholders was ¥25,045,442.29, up 57.73% from ¥15,878,407.77 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥17,703,983.31, showing a significant increase of 114.87% compared to ¥8,239,299.70 in the previous year[5] - Basic earnings per share rose to ¥0.20, a 17.65% increase from ¥0.17 in the previous year[5] - Total operating revenue for Q1 2024 reached ¥110,633,038.63, a significant increase of 65.7% compared to ¥66,839,280.56 in the same period last year[22] - Operating profit for Q1 2024 was CNY 29,566,811.75, up from CNY 18,757,770.10 in the same period last year, indicating a growth of 57.5%[23] - The company reported a total profit of CNY 29,557,191.56 for Q1 2024, compared to CNY 18,824,012.61 in Q1 2023, reflecting a growth of 57.5%[23] Cash Flow - The company's cash flow from operating activities was ¥41,790,114.16, an increase of 9.36% from ¥38,212,822.55 in the same period last year[5] - Cash flow from operating activities for Q1 2024 was CNY 41,790,114.16, an increase from CNY 38,212,822.55 in Q1 2023, reflecting a growth of 4.1%[25] - Cash flow from investing activities generated a net inflow of CNY 65,870,968.18 in Q1 2024, a significant improvement from a net outflow of CNY 109,115,536.52 in Q1 2023[25] - The cash flow from financing activities showed a net outflow of CNY 58,000.00 in Q1 2024, an improvement from a net outflow of CNY 228,700.00 in Q1 2023[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,943,629,937.12, a slight increase of 0.75% from ¥1,929,096,040.45 at the end of the previous year[5] - Total assets amounted to ¥1,943,629,937.12, up from ¥1,929,096,040.45, indicating a growth of 0.8%[21] - Total liabilities decreased to ¥111,992,916.76 from ¥122,504,462.38, a reduction of 8.5%[21] - The company's fixed assets increased to ¥246,169,282.29 from ¥236,830,175.49, reflecting a growth of 3.1%[20] Shareholder Information - Major shareholders include Lu Jun with 28.29% and Lu Weiwei with 16.16% of shares[14] - The company has a total of 34,580,000 shares held by Lu Jun, which are subject to lock-up until January 26, 2025[17] - As of March 31, 2024, the company has a total of 78 million shares under lock-up, with no shares released during the current period[17] - The company has not disclosed any other significant shareholder relationships or actions that may affect its stock[14] Risks and Regulatory Issues - The company reported a significant impact on its future main business revenue and profit due to an import warning issued by the U.S. FDA regarding its subsidiary, Jiangsu Canar Medical Technology Co., Ltd.[15] - The company is facing a significant risk to its revenue and profit from the inability to sell certain medical injection products in the U.S. market[15] - The company is actively communicating with the FDA to resolve the import warning, but the timeline for removal from the warning list remains uncertain[16] - The company has made provisions for inventory impairment in light of the FDA warning's potential impact on financial statements for Q1 2024[16] - The company’s financial performance for Q1 2024 is expected to be adversely affected by the FDA's actions[16] - The company is maintaining a cautious approach to investor communications regarding potential risks associated with the FDA warning[16] Expenses - The company experienced a 65.52% increase in operating income due to higher sales volume compared to the previous year[10] - The company reported a significant increase of 178.82% in selling expenses, primarily due to higher exhibition costs[10] - Research and development expenses for Q1 2024 were ¥5,837,165.26, up 21.9% from ¥4,784,955.79 in Q1 2023[22]